Pre-Earnings Bears Ante Up on IBM

IBM Corp. (IBM) has traditionally struggled in the aftermath of its earnings reports

by

Published on Jan 20, 2015 at 2:25 PM
Updated on Apr 20, 2015 at 5:32 PM

IBM Corp. (NYSE:IBM) is sitting 1.8% lower this afternoon at $154.34, and is scheduled to report fourth-quarter earnings in less than two hours. Ahead of this event, options trading is running at roughly 1.4 times the usual intraday pace, while the stock's 30-day at-the-money implied volatility has popped 3.5% to 26% -- signaling elevated demand for short-term strikes.

IBM's most active option is the weekly 1/23 155-strike put, which is seeing buy-to-open activity. By purchasing these positions, the speculators are wagering on additional downside through this Friday's closing bell -- when the weekly series expires.

Looking back, however, IBM hasn't ended a week south of $155 since early 2011. As such, delta on the now in-the-money put is negative 0.51, meaning the options market is giving the contract about a 1-in-2 chance of being in the money Friday night.

As alluded to earlier, IBM will deliver quarterly results this evening, and this could be a boon for today's option bears. Over the last eight quarters, the shares have averaged a single-session post-earnings loss of 2.8%, including a 7.1% dive last October.

Taking a step back, today's penchant for short-term puts is just business as usual for IBM Corp. (NYSE:IBM). The stock's Schaeffer's put/call open interest ratio (SOIR) of 1.03 ranks in the 74th percentile of its annual range.

Weekly Chart of IBM since January 2011


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.